Clinical Trial

Zimberelimab and Domvanalimab in Combination With Chemotherapy Versus Pembrolizumab With Chemotherapy in Patients With Untreated Metastatic Non-Small Cell Lung Cancer

Study acronym: STAR-121
Active, Not Recruiting Phase 3
View on ClinicalTrials.gov →
Summary
The primary objective of this study is to compare the effect of zimberelimab (ZIM) and domvanalimab (DOM) in combination with chemotherapy relative to pembrolizumab (PEMBRO) in combination with chemotherapy on overall survival (OS) in patients with untreated metastatic non-small cell lung cancer with no actionable genomic alteration.
Protocol Amendment History 34 amendments
This ClinicalTrials.gov record has been amended 34 times since 2022-08-12; most recent amendment 2026-01-28.
Status change: Recruiting → Active, Not Recruiting 2026-01-28
Status change: Active, Not Recruiting → Recruiting 2025-05-16
Status change: Recruiting → Active, Not Recruiting 2024-08-14
Status change: Not Yet Recruiting → Recruiting 2022-10-07
Trial Details
NCT Number NCT05502237
Lead Sponsor Gilead Sciences
Collaborators: Arcus Biosciences, Inc.
Conditions Non-small Cell Lung Cancer
Enrollment 1,021 participants
Start Date 2022-10-12
Primary Completion 2028-06 (estimated)
Study Completion 2029-01 (estimated)
Updated on ClinicalTrials.gov 2026-01-30